WO2009004152A3 - Use of a composition of oligomers of galacturonic acid as an agent for inhibiting degradation of collagen - Google Patents

Use of a composition of oligomers of galacturonic acid as an agent for inhibiting degradation of collagen Download PDF

Info

Publication number
WO2009004152A3
WO2009004152A3 PCT/FR2008/000716 FR2008000716W WO2009004152A3 WO 2009004152 A3 WO2009004152 A3 WO 2009004152A3 FR 2008000716 W FR2008000716 W FR 2008000716W WO 2009004152 A3 WO2009004152 A3 WO 2009004152A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
agent
galacturonic acid
oligomers
collagen
Prior art date
Application number
PCT/FR2008/000716
Other languages
French (fr)
Other versions
WO2009004152A2 (en
Inventor
Said Kamel
Romuald Mentaverri
Jean Marc Lion
Michel Brazier
Josiane Courtois-Sambourg
Original Assignee
Univ Picardie
Said Kamel
Romuald Mentaverri
Jean Marc Lion
Michel Brazier
Josiane Courtois-Sambourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Picardie, Said Kamel, Romuald Mentaverri, Jean Marc Lion, Michel Brazier, Josiane Courtois-Sambourg filed Critical Univ Picardie
Publication of WO2009004152A2 publication Critical patent/WO2009004152A2/en
Publication of WO2009004152A3 publication Critical patent/WO2009004152A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns use of a composition of galacturonic acid oligomers having a degree of polymerization substantially in the range of 5 to 25 as an agent for inhibiting collagen degradation. The invention also concerns the use of such a composition for the preparation of a medicine against osteoporosis, cancer, angiogenesis and the proliferation of metastases.
PCT/FR2008/000716 2007-05-25 2008-05-26 Use of a composition of oligomers of galacturonic acid as an agent for inhibiting degradation of collagen WO2009004152A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0703707A FR2916353B1 (en) 2007-05-25 2007-05-25 PHARMACEUTICAL COMPOSITION FOR PRESERVING COLLAGEN
FR0703707 2007-05-25

Publications (2)

Publication Number Publication Date
WO2009004152A2 WO2009004152A2 (en) 2009-01-08
WO2009004152A3 true WO2009004152A3 (en) 2009-08-06

Family

ID=38859092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000716 WO2009004152A2 (en) 2007-05-25 2008-05-26 Use of a composition of oligomers of galacturonic acid as an agent for inhibiting degradation of collagen

Country Status (2)

Country Link
FR (1) FR2916353B1 (en)
WO (1) WO2009004152A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE672883A (en) * 1964-12-31 1966-03-16
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
US20030100535A1 (en) * 2001-11-21 2003-05-29 Yan Chang Method for controlling angiogenesis in animals
WO2004098543A2 (en) * 2003-05-06 2004-11-18 Laboratoires De Biologie Vegetale Yves Rocher Use of oligogalacturonide-type oligosaccharides in cosmetic, food or dermatological compositions in order to stimulate epidermal cell differentiation
WO2005095463A1 (en) * 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE672883A (en) * 1964-12-31 1966-03-16
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
US20030100535A1 (en) * 2001-11-21 2003-05-29 Yan Chang Method for controlling angiogenesis in animals
WO2004098543A2 (en) * 2003-05-06 2004-11-18 Laboratoires De Biologie Vegetale Yves Rocher Use of oligogalacturonide-type oligosaccharides in cosmetic, food or dermatological compositions in order to stimulate epidermal cell differentiation
WO2005095463A1 (en) * 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRICKLAND F M ET AL: "PRESERVATION OF THE DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO ALLOANTIGEN BY XYLOGLUCANS OR OLIGOGALACTURONIDE DOES NOT CORRELATE WITH THE CAPACITY TO REJECT ULTRAVIOLET-INDUCED SKIN TUMORS IN MICE", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 116, no. 1, January 2001 (2001-01-01), pages 62 - 68, XP001180731, ISSN: 0022-202X *

Also Published As

Publication number Publication date
FR2916353A1 (en) 2008-11-28
FR2916353B1 (en) 2010-09-24
WO2009004152A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2008045534A3 (en) Novel curcumin and tetrahydrocurcumin derivatives
WO2011042613A3 (en) Antimicrobial composition
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
WO2008049020A3 (en) Diclofenac gel
WO2007081991A3 (en) Novel conjugated materials featuring proquinoidal units
WO2008100601A3 (en) Benefit agent delivery compositions
WO2011062965A3 (en) Targeting monomers and polymers having targeting blocks
ZA200707973B (en) Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids
GB0916338D0 (en) Branched addition copolymers in curing systems
WO2008089034A3 (en) Cytokine inhibitors
MX2010003299A (en) Micromirs.
WO2013043796A3 (en) Modified polyethylene compositions
WO2010068862A3 (en) Zwitterionic polymers with therapeutic moieties
WO2011101621A3 (en) Heat transfer compositions
WO2012042224A8 (en) Pharmaceutical composition comprising deferasirox
PL2083809T3 (en) Dietary or pharmaceutical compositions containing tricyclic diterpenes for the treatment of depression.
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
GB2475667A (en) Polymers derived from bis (thienocyclopenta) benzothiadiazole and their use as organic semiconductors
WO2010086881A3 (en) Pharmaceutical compositions comprising phosphate-binding polymer
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2012003501A3 (en) Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2010026590A3 (en) Novel biodegradable adhesive compositions
MY175309A (en) Pharmaceutical composition useful for adhesion prevention or hemostasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08805607

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08805607

Country of ref document: EP

Kind code of ref document: A2